Penningtons Manches Cooper is advising Canaccord Genuity on EDX Medical’s proposed admission to AIM
The corporate team at Penningtons Manches Cooper is advising Canaccord Genuity in its capacity as nominated adviser to EDX Medical Group plc on its move to AIM from the Aquis Stock Exchange, which was announced on 13 April 2026.
EDX Medical develops, validates, and commercialises innovative digital diagnostic products and services, generating valuable biological insights that enable cost effective and timely delivery of personalised treatment for cancer, heart disease, and infectious diseases.
It was admitted to trading on the Aquis Stock Exchange in June 2021 and completed a reverse takeover in November 2022, when it was at a very early stage and had limited commercial operations. Since then, EDX Medical has successfully raised £15.5 million to further develop its business, enter into commercial distribution agreements, and expand its laboratory facilities in personnel.
The directors of EDX Medical recognise that the company will continue to require capital to fulfil its potential, and believe that its access to capital from certain funds, its liquidity profile, and visibility to investors will be improved by the move to AIM.
Admission of EDX Medical’s shares to AIM is expected to take place on 13 May 2026.
The Penningtons Manches Cooper team supporting Canaccord Genuity is led by London-based corporate partner, Seb Orton, with support from associate, Jenny Wright, and trainee, Sheelpa Maroo.
Stuart Andrews, managing director at Canaccord Genuity, said: “We are pleased to support EDX Medical on its move to AIM, which marks an important step in the company’s evolution and growth strategy. The business has made strong progress in developing its diagnostic platform and expanding its operations, and we believe AIM will provide enhanced access to capital and greater visibility with investors as EDX Medical continues to scale. It is a pleasure working alongside Penningtons Manches Cooper, whose commercial and highly responsive approach has been, and continues to be, invaluable throughout the process.”